Frontiers in Microbiology (Nov 2020)

Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea

  • Jae-Hoon Ko,
  • Ji Yeon Lee,
  • Hyun Ah Kim,
  • Seung-Ji Kang,
  • Jin Yang Baek,
  • Su-Jin Park,
  • Miri Hyun,
  • Ik Joon Jo,
  • Chi Ryang Chung,
  • Yae-Jean Kim,
  • Eun-Suk Kang,
  • Young Ki Choi,
  • Hyun-Ha Chang,
  • Sook In Jung,
  • Kyong Ran Peck

DOI
https://doi.org/10.3389/fmicb.2020.587613
Journal volume & issue
Vol. 11

Abstract

Read online

The safety of healthcare workers (HCWs) against severe acute respiratory syndrome virus 2 (SARS-CoV-2) transmission is an important aspect of managing the coronavirus disease 2019 (COVID-19) pandemic. In the South Korea, highly stringent infection prevention and control (IPC) guidelines are implemented, and reports of healthcare-associated SARS-CoV-2 transmission among HCWs are limited. However, subclinical infections may have been missed by the current symptom-based screening strategy. To evaluate the risk of undetected SARS-CoV-2 transmissions from COVID-19 patients to HCWs, we conducted a multicenter seroprevalence study after the first surge of the COVID-19 outbreak. A total of 432 HCWs were evaluated, comprising 309 HCWs designated to laboratory-confirmed COVID-19 patient care and 123 non-designated HCWs. Designated HCWs wore personal protective equipment including an N95 respirator, eye protection, hooded overalls, shoe covers, and inner and outer gloves. Use of a powered air-purifying respirator was recommended for aerosol-generating procedures or long-duration care activities. A high-sensitivity (99.1%) fluorescence immunoassay immunoglobulin G (IgG) kit was used as the initial screening test, and two enzyme-linked immunosorbent assay kits for total and IgG antibodies were used to confirm the test results. A microneutralization test was additionally performed to evaluate the neutralizing activity of positive specimens. Among the evaluated HCWs, none of the non-designated HCWs had a positive result, while one of the HCWs designated for COVID-19 patient care (1/309, 0.3%) was seropositive for SARS-CoV-2 with confirmed neutralizing activity (1:40). This finding suggests that subclinical seroconversion may occur among HCWs caring for COVID-19 patients, although the risk is low under strict IPC guidance.

Keywords